Treatment of patients with the hypereosinophilic syndrome with mepolizumab by Rothenberg Marc E, Klion Amy D, Roufosse Florence E, Kahn Jean Emmanuel, Weller Peter F, Simon Hans-Uwe, Schwartz Lawrence B, Rosenwasser Lanny J, Ring Johannes, Griffin Elaine F, Haig Ann E, Frewer Paul I H, Parkin Jacqueline M, Gleich Gerald J, Mepolizumab HES Study Group in The New England journal of medicine (2008). PubMed

Abstract

The hypereosinophilic syndrome is a group of diseases characterized by persistent blood eosinophilia, defined as more than 1500 cells per microliter with end-organ involvement and no recognized secondary cause. Although most patients have a response to corticosteroids, side effects are common and can lead to considerable morbidity.

[ hide abstract ]

Discussed In Paper

Related In Paper

Variant Annotations

None.